surgery and radiation therapy in brain cancer market

List of Tables:

List of Table

 

Table 1: Summary of Surgery and Radiation Therapy in Brain Cancer Market, Eligible Patient Pool, and Key Events (2018–2026)

Table 2: World Health Organization (WHO) Brain Tumor Grades

Table 3: World Health Organization (WHO) Brain Tumor Grades

Table 4: Clinical presentation of primary brain tumor by location

Table 5: Applicable CPT codes of IMRT/SRS/SBRT

Table 6: CPT codes for IGRT

Table 7: SRT CPT Codes if performed & documented

Table 8: Assessment based on stage

Table 9: Competitive Analysis for Radiotherapy Products used in Treatment of Brain Cancer

Table 10: Competitive Analysis for Surgical Products used in Treatment of Brain Cancer

Table 11: Company Profile: Accuray

Table 12: Company Profile: IBA

Table 13: Company Profile: Eckert & Ziegler AG

Table 14: Company Profile: Hitachi

Table 15: Company Profile: Varian Medical Systems

Table 16: Company Profile: GT Medical Technologies

Table 17: Company Profile: Elekta AB

Table 18: Company Profile: Xoft

Table 19: Company Profile: IntraOp

Table 20: Company Profile: Isoray

Table 21: Company Profile: Mevion

Table 22: Company Profile: ViewRay

Table 23: Company Profile: ZEISS

Table 24: Company Profile: Sensus Healthcare

Table 25: Company Profile: Theragenics

Table 26: Company Profile: Optivus Proton Therapy

Table 27: Company Profile: S.I.T. Sordina IORT Technologies S.p. A.

Table 28: Company Profile: Integra LifeSciences Corporation

Table 29: Company Profile: Misonix Inc

Table 30: Company Profile: Söring GmbH

Table 31: Company Profile: Stryker Corporation

Table 32: Company Profile: Olympus

Table 33: Company Profile: KARL STORZ SE & Co. KG

Table 34: Company Profile: B. Braun Group

Table 35: Company Profile: adeor medical AG

Table 36: Company Profile: Machida Endoscope

Table 37: Company Profile: Clarus Medical

Table 38: Company Profile: Medtronic plc

Table 39: Company Profile: Penumbra, Inc.

Table 40: Incident Patient Population of Primary Brain Tumor in 7MM (2018–2026)

Table 41: Grade-Specific Incident Cases in the 7MM (2018–2026)

Table 42: Type-specific Patient Population of Brain Tumor in the 7MM (2018–2026)

Table 43: Gender-Specific Incident Population of Brain Tumor in the 7MM (2018–2026)

Table 44: Age-specific Patient Population of Brain Tumor in the 7MM (2018–2026)

Table 45: Treatment-specific Patient Population of Brain Tumor in the 7MM (2018–2026)

Table 46: Craniotomy Procedures for Primary Brain Tumor in the 7MM (2018–2026)

Table 47: Incident Patient Population of Brain Tumor in the United States (2018–2026)

Table 48: Grade-Specific Incident Cases in the United States (2018–2026)

Table 49: Type-specific Patient Population of Brain Tumor in the United States (2018–2026)

Table 50: Gender-Specific Incident Population of Brain Tumor in the United States (2018–2026)

Table 51: Age-specific Patient Population of Brain Tumor in the United States (2018–2026)

Table 52: Treatment-specific Patient Population of Brain Tumor in the United States (2018–2026)

Table 53: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026) (2018–2026)

Table 54: Incident Patient Population of Brain Tumor in Germany (2018–2026)

Table 55: Grade-Specific Incident Cases in Germany (2018–2026)

Table 56: Type-specific Patient Population of Brain Tumor in Germany (2018–2026)

Table 57: Gender-Specific Incident Population of Brain Tumor in Germany (2018–2026)

Table 58: Age-specific Patient Population of Brain Tumor in Germany (2018–2026)

Table 59: Treatment-specific Patient Population of Brain Tumor in the Germany (2018–2026)

Table 60: Craniotomy Procedures for Primary Brain Tumor in Germany (2018–2026)

Table 61: Incident Patient Population of Brain Tumor in France (2018–2026)

Table 62: Grade-Specific Incident Cases in France (2018–2026)

Table 63: Type-specific Patient Population of Brain Tumor in France (2018–2026)

Table 64: Gender-Specific Incident Population of Brain Tumor in France (2018–2026)

Table 65: Age-specific Patient Population of Brain Tumor in France (2018–2026)

Table 66: Treatment-specific Patient Population of Brain Tumor in the France (2018–2026)

Table 67: Craniotomy Procedures for Primary Brain Tumor in France (2018–2026)

Table 68: Incident Patient Population of Brain Tumor in Spain (2018–2026)

Table 69: Grade-Specific Incident Cases in Spain (2018–2026)

Table 70: Type-specific Patient Population of Brain Tumor in Spain (2018–2026)

Table 71: Gender-Specific Incident Population of Brain Tumor in Spain (2018–2026)

Table 72: Age-specific Patient Population of Brain Tumor in Spain (2018–2026)

Table 73: Treatment-specific Patient Population of Brain Tumor in Spain (2018–2026)

Table 74: Craniotomy Procedures for Primary Brain Tumor in Spain (2018–2026)

Table 75: Incident Patient Population of Brain Tumor in Italy (2018–2026)

Table 76: Grade-Specific Incident Cases in Italy (2018–2026)

Table 77: Type-specific Patient Population of Brain Tumor in Italy (2018–2026)

Table 78: Gender-Specific Incident Population of Brain Tumor in Italy (2018–2026)

Table 79: Age-specific Patient Population of Brain Tumor in Italy (2018–2026)

Table 80: Treatment-specific Patient Population of Brain Tumor in Italy (2018–2026)

Table 81: Craniotomy Procedures for Primary Brain Tumor in Italy (2018–2026)

Table 82: Incident Patient Population of Brain Tumor in United Kingdom (2018–2026)

Table 83: Grade-Specific Incident Cases in United Kingdom (2018–2026)

Table 84: Type-specific Patient Population of Brain Tumor in United Kingdom (2018–2026)

Table 85: Gender-Specific Incident Population of Brain Tumor in the United Kingdom (2018–2026)

Table 86: Age-specific Patient Population of Brain Tumor in the United Kingdom (2018–2026)

Table 87: Treatment-specific Patient Population of Brain Tumor in the United Kingdom (2018–2026)

Table 88: Craniotomy Procedures for Primary Brain Tumor in the United Kingdom (2018–2026)

Table 89: Incident Patient Population of Brain Tumor in Japan (2018–2026)

Table 90: Grade-Specific Incident Cases in Japan (2018–2026)

Table 91: Type-specific Patient Population of Brain Tumor in Japan (2018–2026)

Table 92: Gender-Specific Incident Population of Brain Tumor in Japan (2018–2026)

Table 93: Age-specific Patient Population of Brain Tumor in Japan (2018–2026)

Table 94: Treatment-specific Patient Population of Brain Tumor in Japan (2018–2026)

Table 95: Craniotomy Procedures for Primary Brain Tumor in Japan (2018–2026)

Table 96: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026)

Table 97: Craniotomy Procedures for Primary Brain Tumor outside the United States (2018–2026)

Table 98: Total Market Size of Surgery and Radiation Therapy in Brain Cancer, in USD Million (2018–2026)

Table 99: Market Share of Conventional Surgery by Treatment Technology in USD Million (2018–2026)

Table 100: Market Share of Conventional Radiation Therapy by Treatment Technology in USD Million (2018–2026)

Table 101: Market Share of Radiation Surgery by Treatment Technology in USD Million (2018–2026)

Table 102: Market Share of Chemo-radiation by Treatment Technology in USD Million (2018–2026)

Table 103: Market Share of Radiation Product by Product Type in USD Million (2018–2026)

Table 104: Market Share of Surgery Products by Product type in USD Million (2018–2026)

Table 105: Market Share of Hospitals by End User in USD Million (2018–2026)

Table 106: Market Share of Radiation centers by End User in USD Million (2018–2026)

Table 107: Market Size of the United States for Surgery and Radiation Products in Brain Tumor by Geography in the 7MM in USD Million (2018–2026)

Table 108: Market Size of Germany for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Table 109: Market Size of France for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Table 110: Market Size of Italy for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Table 111: Market Size of Spain for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Table 112: Market Size of the United Kingdom for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Table 113: Market Size of Japan for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Table 114: Supporting Associations"

List of Figures:

List of Figures

Figure 1: Brain Biopsy

Figure 2: Brain Biopsy

Figure 3: Endoscopic Endonasal Surgery

Figure 4: National Comprehensive Cancer Network (NCCN) Treatment Guidelines for Adult Low-grade (WHO I or II) Glioma/Pilocytic and Inflitrative Supratentorial Astrocytoma/Oligodendroglioma

Figure 5: NCCN Treatment Guidelines for Anaplastic Gliomas

Figure 6: NCCN Treatment Guidelines for Limited Brain Metastases

Figure 7: NCCN Treatment Guidelines for Extensive Brain Metastases.

Figure 8: Medical Linear Accelerator

Figure 9: Cyclotron

Figure 10: Seeds

Figure 11: Applicators

Figure 12: CyberKnife

Figure 13: GammaKnife

Figure 14: Gammatile

Figure 15: Gammatile

Figure 16: Ultrasonic system with aspirators

Figure 17: Class II Device Approval Processes in the United States

Figure 18: Approval Processes in European Countries

Figure 19: Class II Device Approval Processes in Japan

Figure 20: Healthcare Reimbursement System in the US

Figure 21: Key Cross Competition of the Marketed Radiotherapy Devices based on Approval

Figure 22: Key Cross Competition of the Marketed Radiotherapy Devices based on Type of Therapy

Figure 23: Key Cross Competition of the Marketed Radiotherapy Devices based on Product Type

Figure 24: Key Cross Competition of the Marketed Surgical Devices based on Type

Figure 25: Key Cross Competition of the Marketed Surgical Devices based on Product Type

Figure 26: Revenue (as of June 30, 2020)

Figure 27: R&D Expenses (as of June 30, 2020)

Figure 28: Revenue: IBA

Figure 29: R&D Expenses: IBA

Figure 30: Revenue: Eckert & Ziegler AG

Figure 31: R&D Expenses: Eckert & Ziegler AG

Figure 32: Revenue: Hitachi

Figure 33: Revenue: Varian Medical Systems

Figure 34: R&D Expenses: Varian Medical Systems

Figure 35: Revenue: Elekta AB

Figure 36: R&D Expenses: Elekta AB

Figure 37: Revenue: Xoft

Figure 38: Revenue: Isoray

Figure 39: R&D Expenses (as of June 30): Isoray

Figure 40: Revenue: ViewRay

Figure 41: R&D Expenses: ViewRay

Figure 42: Revenue: ZEISS

Figure 43: R&D Expenses: ZEISS

Figure 44: Revenue: Sensus Healthcare

Figure 45: R&D Expenses: Sensus Healthcare

Figure 46: Revenue: Integra LifeSciences Holdings Corporation

Figure 47: R&D Expenses: Integra LifeSciences Holdings Corporation

Figure 48: Revenue: Misonix Inc

Figure 49: R&D Expenses: Misonix Inc

Figure 50: Company Revenue: Stryker (as of December 31, of each year)

Figure 51: R&D Expenditure

Figure 52: Revenue: Olympus (as of March 31, of each year)

Figure 53: R&D Expenses: Olympus

Figure 54: Company Revenue: B. Braun Group

Figure 55: R&D Expenditure: B. Braun Group

Figure 56: Company Revenue: Medtronic (as of April 30, of each year)

Figure 57: R&D Expenses: Medtronic (as of April 30, of each year)

Figure 58: Incident Patient Population for Primary Brain Tumor in 7MM (2018–2026)

Figure 59: Grade-Specific Incident Cases in the 7MM (2018–2026)

Figure 60: Type-specific Patient Population of Brain Tumor in the 7MM (2018–2026)

Figure 61: Gender-Specific Incident Population of Brain Tumor in the 7MM (2018–2026)

Figure 62: Age-specific Patient Population of Brain Tumor in the 7MM (2018–2026)

Figure 63: Treatment-specific Patient Population of Brain Tumor in the 7MM (2018–2026)

Figure 64: Craniotomy Procedures for Primary Brain Tumor in the 7MM (2018–2026)

Figure 65: Incident Patient Population of Brain Tumor in the United States (2018–2026)

Figure 66: Grade-Specific Incident Cases in the United States (2018–2026)

Figure 67: Type-specific Patient Population of Brain Tumor in the United States (2018–2026)

Figure 68: Gender-Specific Incident Population of Brain Tumor in the United States (2018–2026)

Figure 69: Age-specific Patient Population of Brain Tumor in the United States (2018–2026)

Figure 70: Treatment-specific Patient Population of Brain Tumor in the United States (2018–2026)

Figure 71: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026)

Figure 72: Incident Patient Population of Brain Tumor in Germany (2018–2026)

Figure 73: Grade-Specific Incident Cases in Germany (2018–2026)

Figure 74: Type-specific Patient Population of Brain Tumor in Germany (2018–2026)

Figure 75: Gender-Specific Incident Population of Brain Tumor in Germany (2018–2026)

Figure 76: Age-specific Patient Population of Brain Tumor in Germany (2018–2026)

Figure 77: Treatment-specific Patient Population of Brain Tumor in Germany (2018–2026)

Figure 78: Craniotomy Procedures for Primary Brain Tumor in Germany (2018–2026)

Figure 79: Incident Patient Population of Brain Tumor in France (2018–2026)

Figure 80: Grade-Specific Incident Cases in France (2018–2026)

Figure 81: Type-specific Patient Population of Brain Tumor in France (2018–2026)

Figure 82: Gender-Specific Incident Population of Brain Tumor in France (2018–2026)

Figure 83: Age-specific Patient Population of Brain Tumor in France (2018–2026)

Figure 84: Treatment-specific Patient Population of Brain Tumor in France (2018–2026)

Figure 85: Craniotomy Procedures for Primary Brain Tumor in France (2018–2026)

Figure 86: Incident Patient Population of Brain Tumor in Spain (2018–2026)

Figure 87: Grade-Specific Incident Cases in Spain (2018–2026)

Figure 88: Type-specific Patient Population of Brain Tumor in Spain (2018–2026)

Figure 89: Gender-Specific Incident Population of Brain Tumor in Spain (2018–2026)

Figure 90: Age-specific Patient Population of Brain Tumor in Spain (2018–2026)

Figure 91: Treatment-specific Patient Population of Brain Tumor in Spain (2018–2026)

Figure 92: Craniotomy Procedures for Primary Brain Tumor in Spain (2018–2026)

Figure 93: Incident Patient Population of Brain Tumor in Italy (2018–2026)

Figure 94: Grade-Specific Incident Cases in Italy (2018–2026)

Figure 95: Type-specific Patient Population of Brain Tumor in Italy (2018–2026)

Figure 96: Gender-Specific Incident Population of Brain Tumor in Italy (2018–2026)

Figure 97: Age-specific Patient Population of Brain Tumor in Italy (2018–2026)

Figure 98: Treatment-specific Patient Population of Brain Tumor in Italy (2018–2026)

Figure 99: Craniotomy Procedures for Primary Brain Tumor in Italy (2018–2026)

Figure 100: Incident Patient Population of Brain Tumor in United Kingdom (2018–2026)

Figure 101: Grade-Specific Incident Cases in United Kingdom (2018–2026)

Figure 102: Type-specific Patient Population of Brain Tumor in United Kingdom (2018–2026)

Figure 103: Gender-Specific Incident Population of Brain Tumor in United Kingdom (2018–2026)

Figure 104: Age-specific Patient Population of Brain Tumor in United Kingdom (2018–2026)

Figure 105: Treatment-specific Patient Population of Brain Tumor in the United Kingdom (2018–2026)

Figure 106: Craniotomy Procedures for Primary Brain Tumor in the United Kingdom (2018–2026)

Figure 107: Incident Patient Population of Brain Tumor in Japan (2018–2026)

Figure 108: Grade-Specific Incident Cases in Japan (2018–2026)

Figure 109: Type-specific Patient Population of Brain Tumor in Japan (2018–2026)

Figure 110: Gender-Specific Incident Population of Brain Tumor in Japan (2018–2026)

Figure 111: Age-specific Patient Population of Brain Tumor in Japan (2018–2026)

Figure 112: Treatment-specific Patient Population of Brain Tumor in Japan (2018–2026)

Figure 113: Craniotomy Procedures for Primary Brain Tumor in Japan (2018–2026)

Figure 114: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026)

Figure 115: Craniotomy Procedures for Primary Brain Tumor outside the United States (2018–2026)

Figure 116: COVID-19 Impact Analysis on the Market Size in USD Million (2018–2026)

Figure 117: Total Market Size of Surgery and Radiation Therapy in Brain Cancer, in USD Million (2018–2026)

Figure 118: Market Share of Conventional Surgery by Treatment Technology in USD Million (2018–2026)

Figure 119: Market Share of Conventional Radiation Therapy by Treatment Technology in USD Million (2018–2026)

Figure 120: Market Share of Radiation Surgery by Treatment Technology in USD Million (2018–2026)

Figure 121: Market Share of Chemo-radiation by Treatment Technology in USD Million (2018–2026)

Figure 122: Market Share of Radiation Products by Product type in USD Million (2018–2026)

Figure 123: Market Share of Surgery Products by Product type in USD Million (2018–2026)

Figure 124: Market Share of Hospitals by End User in USD Million (2018–2026)

Figure 125: Market Share of Radiation centers by End User in USD Million (2018–2026)

Figure 126: Market Size of the United States for Surgery and Radiation Products in Brain Tumor by Geography in the 7MM in USD Million (2018–2026)

Figure 127: Market Size of Germany for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Figure 128: Market Size of France for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Figure 129: Market Size of Italy for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Figure 130: Market Size of Spain for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Figure 131: Market Size of the United Kingdom for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Figure 132: Market Size of Japan for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)

Surgery and Radiation Therapy in Brain Cancer Companies:

Accuray Incorporated
Ion Beam Applications SA
Eckert & Ziegler
Hitachi, Ltd.
Varian Medical Systems Inc.
GT Medical Technologies Inc.
Elekta AB  (publ)
Xoft, Inc.
IntraOp Medical, Inc
Isoray Inc.
Mevion
ViewRay
ZEISS
Sensus Healthcare
Theragenics
Optivus Proton Therapy
S.I.T. Sordina IORT Technologies S.p.A.
Integra LifeSciences Corporation
Misonix Inc
Söring GmbH
Stryker Corporation
Olympus Corporation
KARL STORZ SE & Co. KG
B. Braun Melsungen AG
adeor medical AG
Machida Endoscopes
Clarus Medical
Medtronic plc
Penumbra Inc.